Peptide News Digest

#Hypoglycemia

1 story

Clinical Trials · View digest

Amylyx's Avexitide Cut Severe Low Blood Sugar Events 55% After Gastric Bypass in Phase 3 LUCIDITY Trial

In 78 adults with post-bariatric hypoglycemia after Roux-en-Y gastric bypass, daily 90 mg avexitide injections lowered the rate of level 2 and level 3 hypoglycemic events to 0.55 a week from 1.24 on placebo over 16 weeks, Amylyx reported at ObesityWeek. Avexitide is a peptide that blocks the GLP-1 receptor, the opposite of weight-loss GLP-1 drugs, to curb the insulin surges behind these crashes. Side effects were mainly stomach and injection-site reactions, with no treatment-related serious adverse events.